New generation of HDAC inhibitor compounds may hold promise since it has been shown that LBH589 increased SMN levels in cells from patients unresponsive to valproic acid [71], and SAHA administration increased lifespan in an SMA mouse model [72]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.